AU Patent

AU2017225236B2 — A lyophilised pharmaceutical formulation and its use

Assigned to Faron Pharmaceuticals Oy · Expires 2022-03-31 · 4y expired

What this patent protects

A pharmaceutical formulation in a lyophilised form, which comprises pharmacologically effective amount of interferon beta-1a as an active ingredient, disaccharides as a bulking agent and a non-ionic surfactant. After reconstitution, the composition can be administered intravenous…

USPTO Abstract

A pharmaceutical formulation in a lyophilised form, which comprises pharmacologically effective amount of interferon beta-1a as an active ingredient, disaccharides as a bulking agent and a non-ionic surfactant. After reconstitution, the composition can be administered intravenously.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017225236B2
Jurisdiction
AU
Classification
—
Expires
2022-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Faron Pharmaceuticals Oy
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.